Blueprint Medicines Share Price Today
(NASDAQ: BPMC)

Name: Blueprint Medicines Share Price Today (NASDAQ: BPMC) - Blueprint Medicines Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Blueprint Medicines share price is $112.44 & ₹9,741.80 as on 1 Feb 2025, 2.30 'hrs' IST

$112.44

▲

-1.61

(-1.41%)

Market is closed - opens 8 PM, 03 Feb 2025

View live Blueprint Medicines share price in Dollar and Rupees. Guide to invest in Blueprint Medicines stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Blueprint Medicines, along with analyst recommendations, forecasts, and comprehensive financials.

Blueprint Medicines share price movements

Today's Low: $112.19
Today's High: $115.95
$112.44
0.22%
Downside
Day's Volatility :3.24%
Upside
3.03%
52 Weeks Low: $72.24
52 Weeks High: $121.90
$112.44
35.75%
Downside
52 Weeks Volatility :40.74%
Upside
7.76%

Blueprint Medicines (BPMC) Returns

Period	Blueprint Medicines Corp	Sector (Health Care)	Index (Russel 2000)
3 Months	24.13%	0.3%	0.0%
6 Months	22.67%	-1.5%	0.0%
1 Year	43.31%	5.0%	0.0%
3 Years	46.27%	12.3%	-12.8%

Blueprint Medicines (BPMC) Key Statistics

in dollars & INR

Previous Close	$114.05
Open	$114.49
Today's High	$115.95
Today's Low	$112.19
Market Capitalization	$7.3B
Today's Volume	$1.3M
52 Week High	$121.9
52 Week Low	$72.24
Revenue TTM	$434.4M
EBITDA	$-262.1M
Earnings Per Share (EPS)	$-2.09
Profit Margin	-29.48%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-49.66%

How to invest in Blueprint Medicines Stock (BPMC) from India?

It is very easy for Indian residents to invest directly in Blueprint Medicines from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Blueprint Medicines stock in both Indian Rupees (INR) and US Dollars (USD). Search for Blueprint Medicines or BPMC on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Blueprint Medicines or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Blueprint Medicines shares which would translate to 0.008 fractional shares of Blueprint Medicines as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Blueprint Medicines, in just a few clicks!

Returns in Blueprint Medicines (BPMC) for Indian investors in Rupees

The Blueprint Medicines stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Blueprint Medicines investment value today

Current value as on today

₹1,45,711

Returns

₹45,711

(+45.71%)

Returns from Blueprint Medicines Stock

₹41,292 (+41.29%)

Dollar Returns

₹4,419 (+4.42%)

Indian investors sentiment towards Blueprint Medicines (BPMC)

33%

Period: Jan 1, 2025 to Jan 31, 2025. Change in 30 Days versus previous period

Search interest for Blueprint Medicines Stock from India on INDmoney has increased by 33% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Blueprint Medicines

BlackRock Inc
11.21%
Vanguard Group Inc
10.52%
T. Rowe Price Associates, Inc.
8.48%
FMR Inc
7.11%
Wellington Management Company LLP
6.24%
State Street Corp
4.35%

Analyst Recommendation on Blueprint Medicines

Buy

73%Buy

17%Hold

8%Sell

Based on 23 Wall street analysts offering stock ratings for Blueprint Medicines(by analysts ranked 0 to 5 stars)

Based on 23 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Blueprint Medicines Stock (BPMC)

What analysts predicted

Upside of 12.06%

Target:

$126.00

Current:

$112.44

Insights on Blueprint Medicines Stock (Ticker Symbol: BPMC)

Price Movement
In the last 1 month, BPMC stock has moved up by 30.8%
Decreasing Revenue
Revenue is down for the last 2 quarters, 138.15M → 128.18M (in $), with an average decrease of 7.2% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, 89.13M → -56.27M (in $), with an average decrease of 84.3% per quarter
BPMC vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 60.3% return, outperforming this stock by 16.9%
BPMC vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 101.4% return, outperforming this stock by 53.5%
Price to Sales
ForBPMC every $1 of sales, investors are willing to pay $16.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.8 for every $1 of sales.

BPMC Blueprint Medicines Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$44.5M	↑ 107.79%
Net Income	$-236.6M	↑ 59.76%
Net Profit Margin	-531.53%	↑ 159.77%

	FY19	Y/Y Change
Revenue	$66.5M	↑ 49.39%
Net Income	$-328.7M	↑ 38.9%
Net Profit Margin	-494.2%	↑ 37.33%

	FY20	Y/Y Change
Revenue	$793.7M	↑ 1093.37%
Net Income	$313.9M	↓ 195.49%
Net Profit Margin	39.54%	↑ 533.74%

	FY21	Y/Y Change
Revenue	$180.1M	↓ 77.31%
Net Income	$-644.1M	↓ 305.2%
Net Profit Margin	-357.67%	↓ 397.21%

	FY22	Y/Y Change
Revenue	$204.0M	↑ 13.3%
Net Income	$-557.5M	↓ 13.44%
Net Profit Margin	-273.24%	↑ 84.43%

	FY23	Y/Y Change
Revenue	$249.4M	↑ 22.22%
Net Income	$-507.0M	↓ 9.06%
Net Profit Margin	-203.3%	↑ 69.94%

	Q2 FY23	Q/Q Change
Revenue	$57.6M	↓ 9.03%
Net Income	$-132.8M	↑ 2.5%
Net Profit Margin	-230.66%	↓ 25.94%

	Q3 FY23	Q/Q Change
Revenue	$56.6M	↓ 1.74%
Net Income	$-133.7M	↑ 0.69%
Net Profit Margin	-236.38%	↓ 5.72%

	Q4 FY23	Q/Q Change
Revenue	$72.0M	↑ 27.21%
Net Income	$-110.9M	↓ 17.05%
Net Profit Margin	-154.14%	↑ 82.24%

	Q1 FY24	Q/Q Change
Revenue	$96.1M	↑ 33.57%
Net Income	$89.1M	↓ 180.36%
Net Profit Margin	92.74%	↑ 246.88%

	Q2 FY24	Q/Q Change
Revenue	$138.2M	↑ 43.74%
Net Income	$-50.0M	↓ 156.09%
Net Profit Margin	-36.19%	↓ 128.93%

	Q3 FY24	Q/Q Change
Revenue	$128.2M	↓ 7.22%
Net Income	$-56.3M	↑ 12.57%
Net Profit Margin	-43.9%	↓ 7.71%

	FY18	Y/Y Change
Profit	$-199.1M	↑ 61.53%

	FY19	Y/Y Change
Profit	$66.5M	↓ 133.41%

	FY20	Y/Y Change
Profit	$793.3M	↑ 1092.73%

	FY21	Y/Y Change
Profit	$162.1M	↓ 79.56%

	FY22	Y/Y Change
Profit	$186.2M	↑ 14.85%

	FY23	Y/Y Change
Profit	$236.6M	↑ 27.04%

	Q2 FY23	Q/Q Change
Profit	$55.2M	↓ 8.09%

	Q3 FY23	Q/Q Change
Profit	$52.0M	↓ 5.85%

	Q4 FY23	Q/Q Change
Profit	$70.2M	↑ 34.9%

	Q1 FY24	Q/Q Change
Profit	$88.1M	↑ 25.58%

	Q2 FY24	Q/Q Change
Profit	$126.9M	↑ 44.07%

	Q3 FY24	Q/Q Change
Profit	$126.3M	↓ 0.55%

	FY18	Y/Y Change
Operating Cash Flow	$-175.0M	↑ 46.01%
Investing Cash Flow	$-161.1M	↑ 112.38%
Financing Cash Flow	$4.5M	↓ 99.18%

	FY19	Y/Y Change
Operating Cash Flow	$-278.0M	↑ 58.86%
Investing Cash Flow	$-16.5M	↓ 89.78%
Financing Cash Flow	$340.6M	↑ 7547.91%

	FY20	Y/Y Change
Operating Cash Flow	$387.0M	↓ 239.21%
Investing Cash Flow	$-434.2M	↑ 2537.25%
Financing Cash Flow	$617.8M	↑ 81.35%

	FY21	Y/Y Change
Operating Cash Flow	$-298.7M	↓ 177.16%
Investing Cash Flow	$-225.9M	↓ 47.99%
Financing Cash Flow	$50.7M	↓ 91.79%

	FY22	Y/Y Change
Operating Cash Flow	$-502.3M	↑ 68.18%
Investing Cash Flow	$-149.5M	↓ 33.79%
Financing Cash Flow	$561.8M	↑ 1007.76%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-130.5M	↑ 6.11%
Investing Cash Flow	$32.1M	↓ 81.44%
Financing Cash Flow	$5.3M	↑ 0.0%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-104.5M	↓ 19.92%
Investing Cash Flow	$-9.6M	↓ 129.89%
Financing Cash Flow	$98.4M	↑ 1757.29%

Blueprint Medicines Technicals Summary

Sell

Neutral

Buy

Blueprint Medicines is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Blueprint Medicines (BPMC) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Blueprint Medicines Corp	30.79%	22.67%	43.31%	46.27%	81.99%
Biontech Se	4.84%	54.26%	30.47%	-32.9%	299.34%
Regeneron Pharmaceuticals, Inc.	-4.49%	-36.24%	-27.73%	9.67%	100.25%
Vertex Pharmaceuticals Incorporated	8.04%	-8.07%	3.23%	72.89%	90.19%
Alnylam Pharmaceuticals, Inc.	18.64%	4.59%	60.15%	90.8%	141.72%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Blueprint Medicines Corp	NA	NA	0.0	-1.33	-0.5	-0.15	NA	4.93
Biontech Se	160.8	NA	0.04	-3.32	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	17.01	17.01	1.06	45.08	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.16	0.49	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Blueprint Medicines Corp	Buy	$7.3B	81.99%	NA	-29.48%
Biontech Se	Buy	$29.0B	299.34%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.5B	100.25%	17.01	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$113.7B	90.19%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$35.3B	141.72%	NA	-15.86%

Blueprint Medicines Dividend announcements

Blueprint Medicines Earnings
Blueprint Medicines’s price-to-earnings ratio stands at None
Read More

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Organization	Blueprint Medicines
Employees	638
CEO	Ms. Kathryn Haviland M.B.A.
Industry	Health Technology

Management People of Blueprint Medicines

Name	Title
Ms. Kathryn Haviland M.B.A.	President, CEO & Director
Mr. Alexis A. Borisy A.M.	Co-Founder & Director
Mr. Michael Landsittel CPA	Chief Financial Officer
Ms. Christina Rossi M.B.A.	Chief Operating Officer
Dr. Percy H. Carter M.B.A., Ph.D.	Chief Scientific Officer
Dr. Fouad Namouni M.D.	President of Research & Development
Ms. Ariel Hurley	Senior VP, Finance & Principal Accounting Officer
Ms. Jenna Cohen	Senior Director & Head of Investor Relations
Ms. Tracey L. McCain Esq.	Executive VP, Chief Legal & Compliance Officer and Secretary
Ms. Debra Durso-Bumpus	Chief People Officer

Important FAQs about investing in BPMC Stock from India :

What is Blueprint Medicines share price today?

Blueprint Medicines share price today stands at $112.44, Open: $114.49 ; Previous Close: $114.05 ; High: $115.95 ; Low: $112.19 ; 52 Week High: $121.90 ; 52 Week Low: $72.24.

The stock opens at $114.49, after a previous close of $114.05. The stock reached a daily high of $115.95 and a low of $112.19, with a 52-week high of $121.90 and a 52-week low of $72.24.

Can Indians buy Blueprint Medicines shares?

Yes, Indians can invest in the Blueprint Medicines (BPMC) from India.

With INDmoney, you can buy Blueprint Medicines at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Blueprint Medicines at zero transaction cost.

How can I buy Blueprint Medicines shares from India?

It is very easy to buy Blueprint Medicines from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Blueprint Medicines (BPMC) be purchased?

Yes, you can buy fractional shares of Blueprint Medicines with INDmoney app.

What are the documents required to start investing in Blueprint Medicines stocks?

To start investing in Blueprint Medicines, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.